Christian Merz
Assessor, Non-Clinical/Quality, Antibody Therapeutics Paul Ehrlich Institute
Following up on over 15 years in preclinical and translational R&D in the biopharmaceutical industry, Christian joined the Paul-Ehrlich-Institut in March 2023. In his function as preclinical assessor for antibody-based therapeutics, fusion proteins and CDx he evaluates CTA/CPS and MAA dossiers, and provides national and EMA scientific advice to Sponsors. Being a scientist by nature, he likes to explore and companion new developments in immunotherapies.
Seminars
Monday 23rd February 2026
Exploring Requirements for Characterisation & Control of ADCs: A Regulator’s Perspective
10:30 am
- Understanding the NCA´s perspective to ADC regulatory CMC as a promising emerging modality
- Offering scientific advice and principles for ADC regulatory CMC strategy
- Laying out commonly asked questions raised by sponsors in Clinical Trial Applications for ADCs
